Form D · Pharmaceuticals
Icagen, Inc.
Durham, NC · CIK 0001518520
Offering snapshot reported Sep 12, 2018 · SEC filing
- Reported sold
- $7.25M Offering amount: $7.25M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 31, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 12, 2018 | Initial | $7,250,000 | No comparison | 1 | SEC filing |
| Aug 15, 2018 | Initial | $500,000 | No comparison | 4 | SEC filing |
| Apr 12, 2018 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| May 25, 2017 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Apr 28, 2017 | Initial | $1,500,000 | No comparison | 3 | SEC filing |
| Jul 8, 2016 | Initial | $1,145,000 | No comparison | 12 | SEC filing |
| Jan 15, 2015 | Amendment | $8,855,000 | $8,806,000vs Dec 16, 2014 | 162 | SEC filing |
| Dec 16, 2014 | Initial | $49,000 | No comparison | 2 | SEC filing |
| May 10, 2013 | Amendment | $3,135,000 | $1,585,000vs Apr 29, 2013 | 61 | SEC filing |
| Apr 29, 2013 | Initial | $1,550,000 | No comparison | 28 | SEC filing |
| May 19, 2011 | Initial | $1,097,950 | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $308K
- Form D file number
- 021-321179
Source: Form D, filed Sep 12, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Cunningham | Executive |
| Clive Kabatznik | Director |
| Mark Korb | Executive |
| Douglas Krafte | Executive |
| Vincent Palmieri | Director |
| Edward Roffman | Director |
| Michael Taglich | Director |
| Timothy Tyson | Director |
| Benjamin Warner | Director |
| Jeremiel Zimmerman | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4222 Emperor Blvd., Suite 350 Research Triangle Park
Durham, NC, 27703
Durham, NC, 27703